A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia (CRC)

What is the purpose of this trial?

This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an effect size estimate for the efficacy of curcumin in improving cognitive functioning in schizophrenia. Secondary goals are to determine the effect of curcumin over time on negative and positive symptoms, in association with inflammatory markers.


Participation Guidelines

Ages: 18 - 65 years

Gender: Both


Yale University School of Medicine

Dates: 03/16/2016 - 03/15/2018

Last Updated: 03/24/2017

Study HIC#: 1412015121

Get Involved

For more information about this study, contact:
Erin L Sullivan
203-974-7317
erin.reutenauer@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Cenk Tek

Principal Investigator

Sub-Investigators